抗胸腺细胞球蛋白治疗肾移植术后早期耐激素的排斥反应(英文)  

TREAMENT OF EARLY STEROID - RESISTANT REJECTION WITH ANTITHYMOCYTE GLOBULIN AFTER KIDNEY TRANSPLANTATION

作　　者：王书龙[1] 张艮甫[1] 黄赤兵[1] 范明齐[1] 刘峰[1] 

机构地区：[1]第三军医大学附属新桥医院肾移植科,重庆400037

出　　处：《中国现代医学杂志》2003年第19期41-43,共3页China Journal of Modern Medicine

摘　　要：目的:观察抗胸腺细胞球蛋白(ATG)治疗肾移植术后早期耐激素排斥反应的效果。方法:对34例尸体肾移植术后3d内应用激素冲击治疗期间发生排斥反应的患者以及手术3d后发生耐激素排斥反应的患者采用ATG治疗。结果:其中32例排斥反应得以逆转,肾功能恢复正常,其治愈率为94.1％。2例虽然控制排斥反应,但其肾功能未能恢复,未行移植肾切除。结论:抗胸腺细胞球蛋白(ATG)治疗早期耐激素排斥反应的效果显著,可以使有耐激素排斥反应的肾移植患者获得良好的肾功能。Objective:To observe the effect of antithymocyte globulin( ATG) on early steroid - resistant rejections after kidney transplantation. Methods:34 steroid - resistant patients were treated with ATG who had rejection during hormone impact treatment within 3 days after transplantation or resistant response 3 days after kidney transplantation. Results: In 32 of 34 steroid - resistant patients after kidney transplantation, their rejections were reversed and their renal function recovered with curing rate of 94.1 %. In 2 of 43 cases, their rejections were controlled, but their renal function did not recover. Conclusions: ATG was a potent immunosuppresant capable of reversing early steroid - resistant rejections. Patients with steroid - ressitant rejectons after transplantation could get favorable renal function.

关 键 词：肾移植 耐激素排斥反应 抗胸腺细胞球蛋白 

分 类 号：R692[医药卫生—泌尿科学]